Karyopharm Therapeutics Inc. (KPTI) is a publicly traded Healthcare sector company. As of May 21, 2026, KPTI trades at $7.85 with a market cap of $161.81M and a P/E ratio of -0.48. KPTI moved +6.69% today. Year to date, KPTI is +7.84%; over the trailing twelve months it is +54.80%. Its 52-week range spans $3.51 to $16.95. Analyst consensus is strong buy with an average price target of $15.83. Rallies surfaces KPTI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Karyopharm Posts Q1 Revenue Growth, Cuts Loss to $22.4M, Completes EC042 Enrollment: Karyopharm Therapeutics saw Q1 revenue growth from favorable gross-to-net dynamics and reduced its net loss to $22.4 million while securing additional financing. Its Phase III SENTRY myelofibrosis trial delivered rapid, deep spleen volume reductions but failed symptom significance, and EC042 enrollment for endometrial cancer is complete with data due mid-2026.
| Metric | Value |
|---|---|
| Price | $7.85 |
| Market Cap | $161.81M |
| P/E Ratio | -0.48 |
| EPS | $-16.16 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.95 |
| 52-Week Low | $3.51 |
| Volume | 223 |
| Avg Volume | 0 |
| Revenue (TTM) | $151.12M |
| Net Income | $-194.97M |
| Gross Margin | 0.00% |
7 analysts cover KPTI: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.83.